Scientific Program

 

Scientific Program

Please click on the day to see the full scientific program of that day.

Friday, March 10, 2017click to expand

 

14:00 - 14:15 Opening Ceremony

14:15 - 15:30 SCIENTIFIC SESSION

Lymphoma biology

Chair: M Dreyling (Germany)

  • Signaling pathways in B cell lymphomas
    G Lenz (Germany)
  • The role of the microenvironment
    M Spaargaren (The Netherlands)

15:30 - 16:00 Coffee break

16:00 - 17:15 SCIENTIFIC SESSION

CNS lymphoma

Chair: M Dreyling (Germany)

  • Biology of CNS lymphoma
    D de Jong (The Netherlands)
  • Treatment of primary CNS lymphoma
    A Ferreri (Italy)
  • Case presentation: A case of central nervous system intravascular lymphoma
    A Devadass (United Kingdom)

17:15 - 18:30 SCIENTIFIC SESSION

Mantle cell lymphoma

Chair: M Dreyling (Germany)

  • Advances in biology
    E Campo (Spain)
  • Current and future treatment of MCL
    M Dreyling (Germany)
  • Case presentation: A case of mantle cell lymphoma presenting with ascites and cutaneous involvement
    D Ozmen (Turkey)

Saturday, March 11, 2017click to expand

 

09:00 - 10:15 SCIENTIFIC SESSION

MALT lymphomas and HCL

Chair: MJ Kersten (The Netherlands)

  • MALT lymphomas
    C Thieblemont (France)
  • Hairy cell leukemia
    T Robak (Poland)
  • Case presentation: Marginal zone lymphoma: A rare case with (misdiagnosed) hepatic presentation
    D Viegas (Portugal)
  • Case presentation: Marginal zone lymphoma: a rare case with (misdiagnosed) hepatic presentation
    D Viegas (Portugal)
10:15 - 10:45 Coffee break

10:45 - 12:00 PANEL DISCUSSION

Can we afford targeted therapy?

Chair: I Aurer (Croatia)

  • Time to publish
    M Federico (Italy)
  • The patient perspective
    U Holtkamp (German Lymphoma Aid)
  • European Medicines Agency
    WD Ludwig (EMA Management Board)
12:00 - 13:00 Lunch

13:00 - 13:45 CASE PITCH SESSION I

Chair: I Aurer (Croatia)

  • Refractory angioimmunoblastic T Cell lymphoma successfully treated with thalidomide with  durable  response
    A Eswedi (United Kingdom)
  • Primary Bone Burkitt's like lymphoma of the skull mimicking meningioma
    R Nader (Lebanon)
  • Extranodal NK/T-cell lymphoma, nasal type
    T Skrypets (Ukraine)
  • Composite Hodgkin and Non-Hodgkin lymphomas: Report of two cases with unusual presentations
    R Nassabein (Lebanon)
  • A case report of lymphoproliferative disorder of NK-cells
    M Studzinski (Poland)
  • Chemoresistent primary adrenal diffuse large B-cell lymphoma presenting with hypercalcemia
    V Vukovic (Serbia)
  • A rare case of ALK-positive anaplastic large cell lymphoma of primary bone lymphoma with a huge soft tissue mass
    L Bao (China)
  • Three Challenging Diagnoses in One Patient: Waldenström's macroglobulinemia, amyloidosis and pulmonary tuberculosis
    A Salihoglu (Turkey)
  • Long term survival of a hepatosplenic T-cell Lymphoma case in the Lebanese population
    S Hanna (Lebanon)
13:45 - 15:00 SCIENTIFIC SESSION

Waldenstrom’s macroglobulinemia

Chair: MJ Kersten (The Netherlands)

  • Biology of WM
    R Owen (United Kingdom)
  • Treatment of WM in 2017
    M Dimopoulos (Greece)
  • Case presentation: Transformed Waldenström's macroglobulinemia: Three populations, one single clone
    A Navarro-Bailon (Spain)
15:00 - 15:20 Coffee break

15:20 - 16:00 CASE PITCH SESSION II

Chair: I Aurer (Croatia)

  • Systemic anaplastic large cell lymphoma: A case report treated with brentuximab vedotin
    J Zanabili (Spain)
  • Central nervous system T-cell lymphoma in a patient with two other previous lymphoproliferative neoplasms
    A Pinto (Portugal)
  • Adult T-cell Leukemia/Lymphoma (ATLL): A rare form of peripheral T-cell lymphoma (PTCL) requiring high levels of diagnostic suspicion
    J Desterro (Portugal)
  • A case of mantle cell lymphoma involving lacrimal gland
    L Bao (China)
  • Chemoresistant subcutaneous panniculitis-like T-cell lymphoma with TCRγδ gene rearrangement
    V Vukovic (Serbia)
  • Small volume B cell clones predict rituxmab responsiveness in patients with neuropathy and IgM paraproteinemia but no overt evidence of lymphoplasmacytic lymphoma (LPL).
    S D'sa (United Kingdom) 
  • A rare case of T-cell prolymphocytic leukemia and splenic marginal zone lymphoma
    T Arias Fernandez (Spain)
  • A case of central nervous system Richter's transformation in chronic lymphocytic leukaemia
    A Devadass (United Kingdom)
16:00 - 17:30 SCIENTIFIC SESSION

MYC-driven lymphomas

Chair: M Federico (Italy)

  • Biology of MYC-driven lymphomas
    G Lenz (Germany)
  • Burkitt lymphoma
    M Chamuleau (The Netherlands)
  • Double hit lymphoma
    I Aurer (Croatia)
17:30 - 18:45 SCIENTIFIC SESSION

Hodgkin lymphoma in elderly patients

Chair: M Federico (Italy)

  • Biology of Hodgkin lymphoma
    R Kuppers (Germany)
  • Targeted therapy in Hodgkin lymphoma
    P Borchmann (Germany)
  • Case presentation: PD-1 blockade as a treatment strategy for lymphomatoid granulomatosis
    E Diehl-Wiesenecker (Germany)

Sunday, March 12, 2017click to expand

 

09:00 - 10:15 SCIENTIFIC SESSION

T cell lymphomas

Chair: M Federico (Italy)

  • Biology of T cell lymphomas
    P Gaulard (France)
  • Novel treatment options
    F d'Amore (Denmark)
  • Case presentation: Complete response to ALK-directed therapy in relapsed refractory extranodal NK / T-cell Lymphoma
    M Binder (USA)

10:15 - 12:15 SCIENTIFIC SESSION

Fighting lymphoma with T cells

  • CAR-T cells
    C Bollard (USA)
10:45 - 11:15 Coffee break

  • Immune checkpoints inhibitors
    S Ansell (USA)
  • Bispecific antibodies
    A Viardot (Germany)

12:15 - 12:30 Closing remarks

12:30 - 13:30 Lunch